T1	Participants 404 540	Patients with stages II and IIIA/B non-small-cell lung cancer received induction paclitaxel 225 mg/m2 intravenously (IV) and carboplatin
T2	Participants 849 934	Stratification factors included age (<70 vs. â‰¥70 years), stage and performance status
T3	Participants 944 1013	243 patients (pts) were enrolled; 120 received AM, 123 received no-AM
